Results 201 to 210 of about 56,531 (280)

Unraveling the Bioactive Compounds and Multi‐Target Mechanisms of the Fructus Aurantii Immaturus‐Bambusae Caulis in Taeniam Herb Pair Against Chronic Gastritis: Integrating Identification of Absorbed Constituents, Targeted Network Pharmacology, and Computational Validation

open access: yesFood Science &Nutrition, Volume 14, Issue 7, July 2026.
This work systematically explored the anti‐chronic gastritis mechanism of the FAI‐BCT herb pair. UPLC‐Q‐TOF‐MS/MS was applied to identify absorbed prototypes and metabolites of FAI‐BCT in rat plasma. Combining database mining, network pharmacology, molecular docking, and molecular dynamics simulation, we screened the key bioactive components and core ...
Yinghua Ma   +4 more
wiley   +1 more source

Neuroendocrine Transformation Without PSA Elevation in High‐Risk Metastatic Castration‐Sensitive Prostate Cancer Under Androgen Receptor Signaling Inhibition: A Case Report

open access: yesIJU Case Reports, Volume 9, Issue 4, July 2026.
ABSTRACT Introduction Neuroendocrine prostate cancer is a rare and highly aggressive variant of prostate cancer with a poor prognosis. We report a case in which metastatic castration‐sensitive prostate cancer directly transformed into neuroendocrine prostate cancer without a corresponding increase in prostate‐specific antigen.
Yoshihiro Nakagami   +9 more
wiley   +1 more source

A Case of Acalculous Cholecystitis During Lenvatinib Plus Pembrolizumab Therapy for Advanced Renal Cell Carcinoma

open access: yesIJU Case Reports, Volume 9, Issue 4, July 2026.
ABSTRACT Introduction Lenvatinib plus pembrolizumab is a standard first‐line therapy for advanced renal cell carcinoma (RCC), and acute acalculous cholecystitis is a rare adverse event. Case Presentation A 60‐year‐old woman with metastatic TFE3‐positive non–clear cell RCC, classified as poor risk by the International Metastatic RCC Database Consortium (
Erika Soga   +9 more
wiley   +1 more source

Cancer Heterogeneity and Cancer Cell Plasticity: Molecular Mechanisms and Precision Therapy

open access: yesMedComm, Volume 7, Issue 7, July 2026.
Tumor progression is driven by heterogeneity occurring across multiple biological scales. At the molecular level, tumor cells exhibit alterations across distinct omics layers, including genomic mutations, epigenomic reprogramming, transcriptional changes, and proteomic remodeling, collectively shaping tumor cell phenotypes and functional states.
Hanwen Hu   +5 more
wiley   +1 more source

Urologic Bacteriome: The Hero or the Villain in Prostate Cancer Onset, Progression, and Treatment?

open access: yesMedicinal Research Reviews, Volume 46, Issue 4, Page 1111-1151, July 2026.
ABSTRACT Prostate cancer (PCa) is the second most frequently diagnosed cancer in men worldwide and the fifth leading cause of cancer‐related mortality, presenting urgent unmet clinical needs in diagnosis and treatment. The recognition of the microbiome as a key factor in human health has prompted numerous studies, revealing an exciting new approach to ...
Lara R. S. Fonseca   +6 more
wiley   +1 more source

Natural Mineral Water (Hora) Supplementation Improves Growth Performance and Carcass Characteristics of Sheep in Ethiopia

open access: yesVeterinary Medicine and Science, Volume 12, Issue 4, July 2026.
This study investigates the effect of natural mineral water (hora) supplementation on sheep performance in Ethiopia. Optimal level of hora supplementation significantly improved nutrient intake, growth performance and carcass characteristics of sheep.
Ashenafi Miresa Kenea   +6 more
wiley   +1 more source

A rare case report of ectopic gallbladder. [PDF]

open access: yesAm J Transl Res
Tian S, Zheng BF, Guo Q, Jia BX.
europepmc   +1 more source

Differential Impact of Metabolic Bariatric Surgery Versus Semaglutide on Adverse Hepatic and Extrahepatic Outcomes in Individuals With Metabolic Dysfunction‐Associated Steatotic Liver Disease and Type 2 Diabetes

open access: yesDiabetes, Obesity and Metabolism, Volume 28, Issue 7, Page 5684-5695, July 2026.
ABSTRACT Aim We compared the impact of metabolic bariatric surgery (MBS) versus semaglutide on clinical outcomes in individuals with metabolic dysfunction‐associated steatotic liver disease (MASLD) and type 2 diabetes (T2D). Methods Patients with MASLD and T2D who had MBS or semaglutide in 2018–2023 were identified (TriNetX database).
Weronika Stupalkowska   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy